Home › Castration-Resistant Prostatic Cancer
Pag-aaral pangklinika para sa Castration-Resistant Prostatic Cancer na nagre-recruit sa U.S.
18 pag-aaral para sa Castration-Resistant Prostatic Cancer ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Los Angeles, CA8 pag-aaral
- New York City, NY7 pag-aaral
- Seattle, WA6 pag-aaral
- Houston, TX6 pag-aaral
- Boston, MA5 pag-aaral
- Pittsburgh, PA4 pag-aaral
- Queens, NY4 pag-aaral
- Philadelphia, PA4 pag-aaral
- Mountain View, CA3 pag-aaral
- Dallas, TX3 pag-aaral
- Nashville, TN3 pag-aaral
- Baltimore, MD3 pag-aaral
- Cincinnati, OH3 pag-aaral
- San Francisco, CA3 pag-aaral
- Minneapolis, MN3 pag-aaral
- St. Louis, MO3 pag-aaral
- Myrtle Beach, SC3 pag-aaral
- Grand Rapids, MI3 pag-aaral
- San Diego, CA3 pag-aaral
- Arlington, VA3 pag-aaral
- Metairie, LA3 pag-aaral
Ayos sa estado
- California11 pag-aaral
- Connecticut3 pag-aaral
- Florida5 pag-aaral
- Illinois3 pag-aaral
- Louisiana3 pag-aaral
- Maryland3 pag-aaral
- Massachusetts5 pag-aaral
- Michigan7 pag-aaral
- Minnesota4 pag-aaral
- Missouri3 pag-aaral
- Nebraska3 pag-aaral
- New Jersey4 pag-aaral
- New York8 pag-aaral
- North Carolina4 pag-aaral
- Ohio4 pag-aaral
- Oregon3 pag-aaral
- Pennsylvania5 pag-aaral
- South Carolina4 pag-aaral
- Tennessee5 pag-aaral
- Texas7 pag-aaral
- Virginia4 pag-aaral
- Washington6 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
Nagre-recruitPhase 3
Edad 18 pataas · Kalalakihan · Na-update Set 25, 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Kalalakihan · Na-update Set 24, 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Kalalakihan · Na-update Set 10, 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Nagre-recruitPhase 1
Edad 18 hanggang 100 · Kalalakihan · Na-update Ago 13, 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 11, 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Kalalakihan · Na-update Ago 10, 2026 · NCT06067841A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 115 · Kalalakihan · Na-update Hul 16, 2026 · NCT07677267A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitObservasyonal na pag-aaral
Edad 18 hanggang 115 · Kalalakihan · Na-update Hul 16, 2026 · NCT07677254A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Kalalakihan · Na-update May 29, 2026 · NCT0725840764Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Nagre-recruitPhase 1/2
Edad 18 pataas · Kalalakihan · Na-update May 6, 2026 · NCT04868604Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Kalalakihan · Na-update Abr 13, 2026 · NCT04337580Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 1/2
Edad 18 pataas · Kalalakihan · Na-update Abr 13, 2026 · NCT06190899Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
Nagre-recruitPhase 1
Edad 18 pataas · Kalalakihan · Na-update Nob 21, 2025 · NCT0574362118F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
Nagre-recruitPhase 4
Edad 18 pataas · Kalalakihan · Na-update Nob 27, 2024 · NCT06706921Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.